bioAffinity Technologies, Inc. (BIAF) Earnings Call Transcripts

bioAffinity Technologies, Inc.'s Latest Earnings Call - June 16, 2026

In the Q2 2026 earnings call for bioAffinity Technologies, Inc., management highlighted the increasing adoption of their CyPath Lung test, which is pivotal for early lung cancer detection. The company reported revenue of $5.2 million for the quarter, a 25% increase year-over-year, and maintained its guidance for the fiscal year at $20 million, signaling strong market demand. Management emphasized the test's high negative predictive value of 99%, which is expected to drive further adoption in clinical settings and reduce unnecessary biopsies, potentially enhancing patient outcomes and operational efficiency.

Reported metrics

Guidance from management

Management maintained its fiscal year 2026 revenue guidance at $20 million, indicating confidence in continued growth driven by increasing adoption of the CyPath Lung test.

What analysts pressed on

Analysts expressed concerns about the scalability of the CyPath Lung test in community settings, particularly regarding the ability to manage the increasing number of lung nodules. There were also questions about the test's integration into existing clinical workflows and its acceptance among healthcare providers.

Main topics on the call

• Revenue Growth Acceleration — bioAffinity reported Q2 2026 revenue of $5.2 million, representing a 25% increase year-over-year. Management noted, "The demand for our CyPath Lung test is rapidly increasing, reflecting our successful market penetration...
• High Negative Predictive Value — The CyPath Lung test demonstrated a negative predictive value of 99%, which management highlighted as a key differentiator. Dr. Baptiste stated, "This test provides objective data that helps reassure patients and reduces...
• Guidance Maintenance — Management maintained its fiscal year 2026 revenue guidance at $20 million, indicating confidence in continued growth. They stated, "We expect to see sustained demand for our products as awareness of lung cancer screenin...
• Market Demand for Noninvasive Testing — There was a strong emphasis on the increasing need for noninvasive testing methods in lung cancer diagnosis. Dr. Gunuganti mentioned, "The anxiety associated with lung nodules can be alleviated significantly with our tes...

Read the full bioAffinity Technologies, Inc. transcript (June 16, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 8 bioAffinity Technologies, Inc. earnings call transcripts on record, spanning April 3, 2023 to July 21, 2026. Based on this history, bioAffinity Technologies, Inc. reports semi-annually. The most recent call on file is dated July 21, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BIAF

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

8

First call

April 3, 2023

Most recent

July 21, 2026

Reporting cadence

semi-annually